Pulmonary arterial hypertension: New insights into the optimal role of current and emerging prostacyclin therapies

American Journal of Cardiology

Volumn 111, Issue 5 SUPPL., 2013, Pages 1A-16A

  Waxman, Aaron B ^a   Zamanian, Roham T ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; PROSTACYCLIN; SELEXIPAG; SILDENAFIL; TADALAFIL; TEZOSENTAN; TREPROSTINIL;

ABDOMINAL DISTENSION; ADD ON THERAPY; ANGINA PECTORIS; ARTERY RESISTANCE; ARTICLE; BACKACHE; CARDIOPULMONARY EXERCISE TEST; CELL PROLIFERATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAM; FAINTNESS; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; GENE MUTATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPOTENSION; INCIDENCE; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; JAW PAIN; LUNG ARTERY PRESSURE; MEDICAL HISTORY; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; PAIN; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; SCLERODERMA; SEX RATIO; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOCYTE AGGREGATION; TONGUE PAIN; TRICUSPID VALVE REGURGITATION; TRISMUS; VASCULAR RESISTANCE; VASODILATATION; VOMITING; WEAKNESS;

EID: 84873647366     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.12.002     Document Type: Article

References (101)

1. G. Strange, R. Fowler, C. Jary, B. Dalton, S. Stewart, and E. Gabbay Integrated care and optimal management of pulmonary arterial hypertension J Multidiscip Healthc 2 2009 67 78
2. A.T. Levinson, and J.R. Klinger Combination therapy for the treatment of pulmonary arterial hypertension Ther Adv Respir Dis 5 2011 419 430
3. G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, C.P. Denton, C.G. Elliott, S.P. Gaine, M.T. Gladwin, Z.C. Jing, M.J. Krowka, D. Langleben, N. Nakanishi, and R. Souza Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 Suppl 1 2009 S43 S54
4. M. Humbert, O. Sitbon, A. Yaïci, D. Montani, D.S. O'Callaghan, X. Jaïs, F. Parent, L. Savale, D. Natali, S. Günther, A. Chaouat, F. Chabot, J.F. Cordier, G. Habib, V. Gressin, Z.C. Jing, R. Souza, G. Simonneau French Pulmonary Arterial Hypertension Network Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 36 2010 549 555
5. A.J. Peacock, N.F. Murphy, J.J. McMurray, L. Caballero, and S. Stewart An epidemiological study of pulmonary arterial hypertension Eur Respir J 30 2007 104 109
6. E. Hachulla, and J.G. Coghlan A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism Ann Rheum Dis 63 2004 1009 1014
7. N. Galiè, A. Manes, L. Uguccioni, F. Serafini, M. De Rosa, A. Branzi, and B. Magnani Primary pulmonary hypertension: insights into pathogenesis from epidemiology Chest 114 1998 184S 194S
8. G.E. D'Alonzo, R.J. Barst, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, K.M. Detre, A.P. Fishman, R.M. Goldring, B.M. Groves, J.T. Kernis, P.S. Levy, G.G. Pietra, L.M. Reid, J.T. Reeves, S. Rich, C.E. Vreim, G.W. Williams, and M. Wu Survival in patients with primary pulmonary hypertension: results from a national prospective registry Ann Intern Med 115 1991 343 349
9. V.V. McLaughlin, O. Sitbon, D.B. Badesch, R.J. Barst, C. Black, N. Galiè, M. Rainisio, G. Simonneau, and L.J. Rubin Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249
10. V.V. McLaughlin, S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, M.A. Mathier, M.D. McGoon, M.H. Park, R.S. Rosenson, L.J. Rubin, V.F. Tapson, J. Varga American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. American Heart Association, American College of Chest Physicians, American Thoracic Society, Inc, Pulmonary Hypertension Association ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
11. R. Condliffe, D.G. Kiely, A.J. Peacock, P.A. Corris, J.S. Gibbs, F. Vrapi, C. Das, C.A. Elliot, M. Johnson, J. DeSoyza, C. Torpy, K. Goldsmith, D. Hodgkins, R.J. Hughes, J. Pepke-Zaba, and J.G. Coghlan Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era Am J Respir Crit Care Med 1792 2009 151 157
12. L. Chung, J. Liu, L. Parsons, P.M. Hassoun, M. McGoon, D.B. Badesch, D.P. Miller, M.R. Nicolls, and R.T. Zamanian Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype Chest 1386 2010 1383 1394
13. S. Rich, D.R. Dantzker, S.M. Ayres, E.H. Bergofsky, B.H. Brundage, K.M. Detre, A.P. Fishman, R.M. Goldring, B.M. Groves, and S.K. Koerner Primary pulmonary hypertension: a national prospective study Ann Intern Med 107 1987 216 223
14. D.B. Badesch, H.C. Champion, M.A. Sanchez, M.M. Hoeper, J.E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R.J. Oudiz, and A. Torbicki Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 54 Suppl 1 2009 S55 S66
15. J.J. Tolle, A.B. Waxman, T.L. Van Horn, P.P. Pappagianopoulos, and D.M. Systrom Exercise-induced pulmonary arterial hypertension Circulation 118 2008 2183 2189
16. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), N. Galiè, M.M. Hoeper, M. Humbert, A. Torbicki, J.L. Vachiery, J.A. Barbera, M. Beghetti, P. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, and G. Simonneau Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Respir J 34 2009 1219 1263
17. N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki, M. Kakishita, K. Fukushima, Y. Okano, N. Nakanishi, K. Miyatake, and K. Kangawa Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865 870
18. O. Sitbon, M. Humbert, X. Jaïs, V. Ioos, A.M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Hervé, and G. Simonneau Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111
19. S. Chopra, D.K. Badyal, P.C. Baby, and D. Cherian Pulmonary arterial hypertension: advances in pathophysiology and management Indian J Pharmacol 44 2012 4 11
20. R.T. Schermuly, H.A. Ghofrani, M.R. Wilkins, and F. Grimminger Mechanisms of disease: pulmonary arterial hypertension Nat Rev Cardiol 8 2011 443 455
21. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
22. G.G. Pietra, F. Capron, S. Stewart, O. Leone, M. Humbert, I.M. Robbins, L.M. Reid, and R.M. Tuder Pathologic assessment of vasculopathies in pulmonary hypertension J Am Coll Cardiol 43 12 suppl S 2004 25S 32S
23. M. Humbert, N.W. Morrell, S.L. Archer, K.R. Stenmark, M.R. MacLean, I.M. Lang, B.W. Christman, E.K. Weir, O. Eickelberg, N.F. Voelkel, and M. Rabinovitch Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 12 suppl S 2004 13S 24S
24. L.J. Rubin, and S. Roux Bosentan: a dual endothelin receptor antagonist Expert Opin Invest Drugs 11 2002 991 1002
25. R. Budhiraja, R.M. Tuder, and P.M. Hassoun Endothelial dysfunction in pulmonary hypertension Circulation 109 2004 159 165
26. N.H. Kim, and L.J. Rubin Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension J Cardiovasc Pharmacol Ther 7 2002 9 19
27. B. Hocher, A. Schwarz, K.A. Fagan, C. Thöne-Reineke, K. El-Hag, H. Kusserow, S. Elitok, C. Bauer, H.H. Neumayer, D.M. Rodman, and F. Theuring Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice Am J Respir Cell Mol Biol 23 2000 19 26
28. X. Shi-Wen, C.P. Denton, M.R. Dashwood, A.M. Holmes, G. Bou-Gharios, J.D. Pearson, C.M. Black, and D.J. Abraham Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1 J Invest Dermatol 116 2001 417 425
29. V.V. McLaughlin Looking to the future: a new decade of pulmonary arterial hypertension therapy Eur Respir Rev 20 2011 262 269
30. J.H. Newman, R.C. Trembath, J.A. Morse, E. Grunig, J.E. Loyd, S. Adnot, F. Coccolo, C. Ventura, J.A. Phillips III, J.A. Knowles, B. Janssen, O. Eickelberg, S. Eddahibi, P. Herve, W.C. Nichols, and G. Elliott Genetic basis of pulmonary arterial hypertension: current understanding and future directions J Am Coll Cardiol 43 12 suppl S 2004 33S 39S
31. J.R. Thomson, R.D. Machado, M.W. Pauciulo, N.V. Morgan, M. Humbert, G.C. Elliott, K. Ward, M. Yacoub, G. Mikhail, P. Rogers, J. Newman, L. Wheeler, T. Higenbottam, J.S. Gibbs, J. Egan, A. Crozier, A. Peacock, R. Allcock, P. Corris, J.E. Loyd, R.C. Trembath, and W.C. Nichols Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family J Med Genet 37 2000 741 745
32. J.D. Cogan, C.L. Vnencak-Jones, J.A. Phillips III, K.B. Lane, L.A. Wheeler, I.M. Robbins, G. Garrison, L.K. Hedges, and J.E. Loyd Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension Genet Med 7 2005 169 174
33. N. Kimura, R. Matsuo, H. Shibuya, K. Nakashima, and T. Taga BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6 J Biol Chem 275 2000 17647 17652
34. R.C. Trembath, J.R. Thomson, R.D. Machado, N.V. Morgan, C. Atkinson, I. Winship, G. Simonneau, N. Galie, J.E. Loyd, M. Humbert, W.C. Nichols, N.W. Morrell, J. Berg, A. Manes, J. McGaughran, M. Pauciulo, and L. Wheeler Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia N Engl J Med 345 2001 325 334
35. E. Marcos, E. Fadel, O. Sanchez, M. Humbert, P. Dartevelle, G. Simonneau, M. Hamon, S. Adnot, and S. Eddahibi Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension Circ Res 94 2004 1263 1270
36. L. Abenhaim, Y. Moride, F. Brenot, S. Rich, J. Benichou, X. Kurz, T. Higenbottam, C. Oakley, E. Wouters, M. Aubier, G. Simonneau, and B. Bégaud Appetite-suppressant drugs and the risk of primary pulmonary hypertension N Engl J Med 335 1996 609 616
37. J. McMurray, P. Bloomfield, and H.C. Miller Irreversible pulmonary hypertension after treatment with fenfluramine BMJ 293 1986 51 52
38. US Food and Drug Administration. FDA announces withdrawal of fenfluramine and dexfenfluramine (Fen-Phen). September 15, 1997. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed September 12, 2012.
39. M.A. Gomez-Sanchez, C. Saenz de la Calzada, C. Gomez-Pajuelo, F.J. Martinez-Tello, M.J. Mestre de Juan, and T.N. James Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome J Am Coll Cardiol 18 1991 1539 1545
40. K.E. Sack, and L.A. Criswell Eosinophilia-myalgia syndrome: the aftermath South Med J 85 1992 878 882
41. T.E. Albertson, W.F. Walby, and R.W. Derlet Stimulant-induced pulmonary toxicity Chest 108 1995 1140 1149
42. K.M. Chin, R.N. Channick, and L.J. Rubin Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130 2006 1657 1663
43. M.D. McGoon, and D.P. Miller REVEAL: a contemporary US pulmonary arterial hypertension registry Eur Respir Rev 21 2012 8 18
44. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
45. R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, D.B. Badesch, B.M. Groves, V.F. Tapson, R.C. Bourge, B.H. Brundage, S.K. Koerner, D. Langleben, C.A. Keller, S. Murali, B.F. Uretsky, L.M. Clayton, M.M. Jöbsis, S.D. Blackburn, D. Shortino, J.W. Crow Primary Pulmonary Hypertension Study Group A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 301
46. R. Badagliacca, B. Pezzuto, R. Poscia, M. Mancone, S. Papa, S. Marcon, G. Valli, G. Sardella, F. Ferrante, C. Iacoboni, D. Parola, F. Fedele, and C.D. Vizza Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral J Heart Lung Transplant 31 2012 364 372
47. J.L. Vachiéry Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy Adv Ther 28 2011 251 269
48. R.L. Benza, D.P. Miller, M. Gomberg-Maitland, R.P. Frantz, A.J. Foreman, C.S. Coffey, A. Frost, R.J. Barst, D.B. Badesch, C.G. Elliott, T.G. Liou, and M.D. McGoon Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
49. Sitbon O, Humbert M, Simonneau G, Lemarie JC, Miller D, Muros Le Rouzic E, Gressin V, Badesch D, Benza R, Elliott CG, Frost A, McGoon M. External validation of the REVEAL risk score calculator for PAH survival: a French pulmonary hypertension network analysis. Presented at the Annual Meeting of the European Respiratory Society, September 2, 2012, Vienna, Austria, OP 369. Available at: http://www.ers-education.org/ersMade/abstract-print-12/main- frameset.htm. Accessed September 19, 2012.
50. Hopkins W, Rubin LJ. Treatment of pulmonary hypertension in adults. Last updated August 16, 2012. Available at: www.UpToDate.com. Accessed September 5, 2012.
51. O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Hervé, M. Rainisio, and G. Simonneau Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
52. J. Hiremath, S. Thanikachalam, K. Parikh, S. Shanmugasundaram, S. Bangera, L. Shapiro, G.B. Pott, C.L. Vnencak-Jones, C. Arneson, M. Wade, R.J. White TRUST Study Group Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial J Heart Lung Transplant 29 2010 137 149
53. F. López-Medrano, M. Fernández-Ruiz, M.J. Ruiz-Cano, E. Barrios, M. Vicente-Hernández, J.M. Aguado, and P. Escribano High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil Arch Bronconeumol 48 2012 443 447
54. G. Simonneau, R.J. Barst, N. Galie, R. Naeije, S. Rich, R.C. Bourge, A. Keogh, R. Oudiz, A. Frost, S.D. Blackburn, J.W. Crow, L.J. Rubin Treprostinil Study Group Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
55. R.J. Barst, N. Galie, R. Naeije, G. Simonneau, R. Jeffs, C. Arneson, and L.J. Rubin Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203
56. H. Olschewski, G. Simonneau, N. Galiè, T. Higenbottam, R. Naeije, L.J. Rubin, S. Nikkho, R. Speich, M.M. Hoeper, J. Behr, J. Winkler, O. Sitbon, W. Popov, H.A. Ghofrani, A. Manes, D.G. Kiely, R. Ewert, A. Meyer, P.A. Corris, M. Delcroix, M. Gomez-Sanchez, H. Siedentop, W. Seeger Aerosolized Iloprost Randomized Study Group Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
57. C.F. Opitz, R. Wensel, J. Winkler, M. Halank, L. Bruch, F.X. Kleber, G. Höffken, S.D. Anker, A. Negassa, S.B. Felix, R. Hetzer, and R. Ewert Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Eur Heart J 26 2005 1895 1902
58. H. Olschewski, M.M. Hoeper, J. Behr, R. Ewert, A. Meyer, M.M. Borst, J. Winkler, M. Pfeifer, H. Wilkens, H.A. Ghofrani, S. Nikkho, and W. Seeger Long-term therapy with inhaled iloprost in patients with pulmonary hypertension Respir Med 104 2010 731 740
59. R.N. Channick, H. Olschewski, W. Seeger, T. Staub, R. Voswinckel, and L.J. Rubin Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension J Am Coll Cardiol 48 2006 1433 1437
60. V.V. McLaughlin, R.L. Benza, L.J. Rubin, R.N. Channick, R. Voswinckel, V.F. Tapson, I.M. Robbins, H. Olschewski, M. Rubenfire, and W. Seeger Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
61. V.A. de Jesus Perez, E. Rosenzweig, L.J. Rubin, D. Poch, A. Bajwa, M. Park, M. Jain, R.C. Bourge, K. Kudelko, E. SpiekerkoetterLiu, J. Liu, A. Hsi, and R.T. Zamanian Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension Am J Cardiol 110 2012 1546 1550
62. R. Agarwal, and M. Gomberg-Maitland Current therapeutics and practical management strategies for pulmonary arterial hypertension Am Heart J 162 2011 201 213
63. R.N. Channick, R. Voswinckel, and L.J. Rubin Inhaled treprostinil: a therapeutic review Drug Des Devel Ther 6 2012 19 28
64. R. Voswinckel, B. Enke, F. Reichenberger, M. Kohstall, A. Kreckel, S. Krick, H. Gall, T. Gessler, T. Schmehl, H.A. Ghofrani, R.T. Schermuly, F. Grimminger, L.J. Rubin, W. Seeger, and H. Olschewski Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies J Am Coll Cardiol 48 2006 1672 1681
65. R.C. Bourge, V.F. Tapson, Z. Safdar, R.L. Benza, R.N. Channick, E.B. Rosenzweig, S. Shapiro, R. James White, C. Shane McSwain, S. Karl Gotzkowsky, A.C. Nelsen, and L.J. Rubin Safely transitioning from inhaled iloprost to inhaled treprostinil sodium - results from a multicenter open-label study in patients with pulmonary arterial hypertension Am J Respir Crit Care Med 181 2010 A3342
66. B. Mukherjee, and L. Howard Combination therapy in pulmonary arterial hypertension: do we have the right strategy? Expert Rev Respir Med 5 2011 191 205
67. Y. Bai, L. Sun, S. Hu, and Y. Wei Combination therapy in pulmonary arterial hypertension: a meta-analysis Cardiology 120 2011 157 165
68. M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galiè, A. Boonstra, L.J. Rubin, E.M. Horn, A. Manes, and G. Simonneau Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359
69. V.V. McLaughlin, R.J. Oudiz, A. Frost, V.F. Tapson, S. Murali, R.N. Channick, D.B. Badesch, R.J. Barst, H.H. Hsu, and L.J. Rubin Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263
70. H.A. Ghofrani, R. Wiedemann, F. Rose, H. Olschewski, R.T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension Ann Intern Med 136 2002 515 522
71. G. Simonneau, L.J. Rubin, N. Galiè, R.J. Barst, T.R. Fleming, A.E. Frost, P.J. Engel, M.R. Kramer, G. Burgess, L. Collings, N. Cossons, O. Sitbon, D.B. Badesch PACES Study Group Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
72. S.Y. Kim, J.K. Shim, Y.H. Shim, S.W. Hong, K.H. Choi, and Y.L. Kwak Sildenafil and beraprost combination therapy in patients with pulmonary hypertension undergoing valvular heart surgery J Heart Valve Dis 19 2010 333 340
73. N. Galiè, L.J. Rubin, M. Hoeper, P. Jansa, H. Al-Hiti, G. Meyer, E. Chiossi, A. Kusic-Pajic, and G. Simonneau Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100
74. N. Galiè, B.H. Brundage, H.A. Ghofrani, R.J. Oudiz, G. Simonneau, Z. Safdar, S. Shapiro, R.J. White, M. Chan, A. Beardsworth, L. Frumkin, R.J. Barst Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
75. M.M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Eur Respir J 22 2003 330 334
76. M.M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur Respir J 26 2005 858 863
77. H.J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler Bosentan improves exercise tolerance and TEI index in patients with pulmonary hypertension and prostanoid therapy Chest 128 2005 709 713
78. M.M. Hoeper, H. Leuchte, M. Halank, H. Wilkens, F.J. Meyer, H.J. Seyfarth, R. Wensel, F. Ripken, H. Bremer, S. Kluge, G. Hoeffken, and J. Behr Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Eur Respir J 28 2006 691 694
79. R.L. Benza, B.K. Rayburn, J.A. Tallaj, S.V. Pamboukian, and R.C. Bourge Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan Chest 134 2008 139 145
80. S. Akagi, H. Matsubara, K. Miyaji, E. Ikeda, K. Dan, N. Tokunaga, K. Hisamatsu, M. Munemasa, Y. Fujimoto, and T. Ohe Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol Circ J 72 2008 1142 1146
81. W. Jacobs, A. Boonstra, J.T. Marcus, P.E. Postmus, and A. Vonk-Noordegraaf Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy J Heart Lung Transplant 28 2009 280 284
82. H.A. Ghofrani, F. Rose, R.T. Schermuly, H. Olschewski, R. Wiedemann, N. Weissmann, C. Schudt, H. Tenor, W. Seeger, and F. Grimminger Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension Crit Care Med 30 2002 2489 2492
83. H.A. Ghofrani, F. Rose, R.T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, and F. Grimminger Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 2003 158 164
84. M. Gomberg-Maitland, V. McLaughlin, M. Gulati, and S. Rich Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension Am J Cardiol 96 2005 1334 1336
85. M.J. Ruiz, P. Escribano, J.F. Delgado, C. Jiménez, R. Tello, M.A. Gómez, and C.S. de la Calzada Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience J Heart Lung Transplant 25 2006 1353 1357
86. F. Reichenberger, R. Voswinckel, E. Steveling, B. Enke, A. Kreckel, H. Olschewski, F. Grimminger, W. Seeger, and H.A. Ghofrani Sildenafil treatment for portopulmonary hypertension Eur Respir J 28 2006 563 567
87. M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 24 2004 1007 1010
88. K. Lunze, N. Gilbert, S. Mebus, O. Miera, W. Fehske, F. Uhlemann, E.G. Mühler, P. Ewert, P.E. Lange, F. Berger, and I. Schulze-Neick First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension Eur J Clin Invest 36 Suppl 3 2006 32 38
89. S.A. van Wolferen, A. Boonstra, J.T. Marcus, K.M. Marques, J.G. Bronzwaer, P.E. Postmus, and A. Vonk-Noordegraaf Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension Heart 92 2006 1860 1861
90. S.C. Mathai, R.E. Girgis, M.R. Fisher, H.C. Champion, T. Housten-Harris, A. Zaiman, and P.M. Hassoun Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur Respir J 29 2007 469 475
91. E. Gruenig, E. Michelakis, J.L. Vachiéry, C.D. Vizza, F.J. Meyer, M. Doelberg, D. Bach, J. Dingemanse, and N. Galiè Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study J Clin Pharmacol 49 2009 1343 1352
92. A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (FREEDOM-C2). Available at: ClinicalTrials.gov, clinical trial no. NCT00887978. Accessed September 5, 2012.
93. An open-label extension trial of UT-15C SR in subjects with pulmonary arterial hypertension (FREEDOM-EXT). Available at: ClinicalTrials.gov, clinical trial no. NCT01027949. Accessed September 5, 2012.
94. An open-label, long-term study of oral treprostinil in subjects with pulmonary arterial hypertension. Available at: ClinicalTrials.gov, clinical trial no. NCT01560637. Accessed September 5, 2012.
95. Trial of the early combination of oral treprostinil with a PDE-5 inhibitor or ERA in subjects with pulmonary arterial hypertension (FREEDOM-Ev). Available at: ClinicalTrials.gov, clinical trial no. NCT01560624. Accessed September 5, 2012.
96. Remodulin® to oral treprostinil transition. Available at: ClinicalTrials.gov, clinical trial no. NCT01588405. Accessed September 5, 2012.
97. V.F. Tapson, F. Torres, F. Kermeen, A.M. Keogh, R.P. Allen, R.P. Frantz, D.B. Badesch, A.E. Frost, S.M. Shapiro, K. Laliberte, J. Sigman, C. Arneson, and N. Galiè Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012 May 24 [Epub ahead of print]
98. United Therapeutics. UT-15C treprostinil diethanolamine sustained release tablets (oral treprostinil). Available at: http://www.unither.com/oral- treprostinil-for-pah/. Accessed September 5, 2012.
99. ACT-293987 in pulmonary arterial hypertension. Available at: ClinicalTrials.gov, clinical trial no. NCT01112306. Accessed September 5, 2012.
100. ACT-293987 in pulmonary arterial hypertension. Available at: ClinicalTrials.gov, clinical trial no. NCT01106014. Accessed September 5, 2012.
101. R.J. Barst, J.S. Gibbs, H.A. Ghofrani, M.M. Hoeper, V.V. McLaughlin, L.J. Rubin, O. Sitbon, V.F. Tapson, and N. Galiè Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 Suppl 1 2009 S78 S84